The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID‐19 infection
Acetylsalicylic acid (aspirin) is commonly used for primary and secondary prevention of cardiovascular diseases. Aspirin use is associated with better outcomes among COVID‐19 positive patients. We hypothesized that the aspirin use for primary cardiovascular disease prevention might have a protective...
Saved in:
| Published in | The FEBS journal Vol. 288; no. 17; pp. 5179 - 5189 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Blackwell Publishing Ltd
01.09.2021
John Wiley and Sons Inc |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Acetylsalicylic acid (aspirin) is commonly used for primary and secondary prevention of cardiovascular diseases. Aspirin use is associated with better outcomes among COVID‐19 positive patients. We hypothesized that the aspirin use for primary cardiovascular disease prevention might have a protective effect on COVID‐19 susceptibility and disease duration. We conducted a retrospective population‐based cross‐sectional study, utilizing data from the Leumit Health Services database. The proportion of patients treated with aspirin was significantly lower among the COVID‐19‐positive group, as compared to the COVID‐19‐negative group [73 (11.03%) vs. 1548 (15.77%); P = 0.001]. Aspirin use was associated with lower likelihood of COVID‐19 infection, as compared to nonusers (adjusted OR 0.71 (95% CI, 0.52 to 0.99; P = 0.041). Aspirin users were older (68.06 ± 12.79 vs. 56.63 ± 12.28 years of age; P < 0.001), presented a lower BMI (28.77 ± 5.4 vs. 30.37 ± 4.55; P < 0.0189), and showed higher prevalence of hypertension (56, 76.71%), diabetes (47, 64.38%), and COPD (11, 15.07%) than the aspirin nonusers (151, 25.64%, P < 0.001; 130, 22.07%, P < 0.001; and 43, 7.3%, P = 0.023, respectively). Moreover, COVID‐19 disease duration (considered as the time between the first positive and second negative COVID‐19 RT–PCR test results) among aspirin users was significantly shorter, as compared to aspirin nonusers (19.8 ± 7.8 vs. 21.9 ± 7.9 P = 0.045). Among hospitalized COVID‐positive patients, a higher proportion of surviving subjects were treated with aspirin (20, 19.05%), as opposed to 1 dead subject (14.29%), although this difference was not significant (P = 0.449). In conclusion, we observed an inverse association between the likelihood of COVID‐19 infection, disease duration and mortality, and aspirin use for primary prevention.
Acetylsalicylic acid (aspirin) is used for the prevention of cardiovascular diseases and might be associated with better outcomes among COVID‐19 patients. We hypothesized that aspirin use for primary cardiovascular disease prevention might have effects on COVID‐19 susceptibility. We conducted a retrospective population‐based study, utilizing data from the Leumit Health Services database. We observed an inverse association between the likelihood of COVID‐19 infection, disease duration and mortality, and aspirin use for primary prevention. |
|---|---|
| AbstractList | Acetylsalicylic acid (aspirin) is commonly used for primary and secondary prevention of cardiovascular diseases. Aspirin use is associated with better outcomes among COVID-19 positive patients. We hypothesized that the aspirin use for primary cardiovascular disease prevention might have a protective effect on COVID-19 susceptibility and disease duration. We conducted a retrospective population-based cross-sectional study, utilizing data from the Leumit Health Services database. The proportion of patients treated with aspirin was significantly lower among the COVID-19-positive group, as compared to the COVID-19-negative group [73 (11.03%) vs. 1548 (15.77%); P = 0.001]. Aspirin use was associated with lower likelihood of COVID-19 infection, as compared to nonusers (adjusted OR 0.71 (95% CI, 0.52 to 0.99; P = 0.041). Aspirin users were older (68.06 ± 12.79 vs. 56.63 ± 12.28 years of age; P < 0.001), presented a lower BMI (28.77 ± 5.4 vs. 30.37 ± 4.55; P < 0.0189), and showed higher prevalence of hypertension (56, 76.71%), diabetes (47, 64.38%), and COPD (11, 15.07%) than the aspirin nonusers (151, 25.64%, P < 0.001; 130, 22.07%, P < 0.001; and 43, 7.3%, P = 0.023, respectively). Moreover, COVID-19 disease duration (considered as the time between the first positive and second negative COVID-19 RT-PCR test results) among aspirin users was significantly shorter, as compared to aspirin nonusers (19.8 ± 7.8 vs. 21.9 ± 7.9 P = 0.045). Among hospitalized COVID-positive patients, a higher proportion of surviving subjects were treated with aspirin (20, 19.05%), as opposed to 1 dead subject (14.29%), although this difference was not significant (P = 0.449). In conclusion, we observed an inverse association between the likelihood of COVID-19 infection, disease duration and mortality, and aspirin use for primary prevention.Acetylsalicylic acid (aspirin) is commonly used for primary and secondary prevention of cardiovascular diseases. Aspirin use is associated with better outcomes among COVID-19 positive patients. We hypothesized that the aspirin use for primary cardiovascular disease prevention might have a protective effect on COVID-19 susceptibility and disease duration. We conducted a retrospective population-based cross-sectional study, utilizing data from the Leumit Health Services database. The proportion of patients treated with aspirin was significantly lower among the COVID-19-positive group, as compared to the COVID-19-negative group [73 (11.03%) vs. 1548 (15.77%); P = 0.001]. Aspirin use was associated with lower likelihood of COVID-19 infection, as compared to nonusers (adjusted OR 0.71 (95% CI, 0.52 to 0.99; P = 0.041). Aspirin users were older (68.06 ± 12.79 vs. 56.63 ± 12.28 years of age; P < 0.001), presented a lower BMI (28.77 ± 5.4 vs. 30.37 ± 4.55; P < 0.0189), and showed higher prevalence of hypertension (56, 76.71%), diabetes (47, 64.38%), and COPD (11, 15.07%) than the aspirin nonusers (151, 25.64%, P < 0.001; 130, 22.07%, P < 0.001; and 43, 7.3%, P = 0.023, respectively). Moreover, COVID-19 disease duration (considered as the time between the first positive and second negative COVID-19 RT-PCR test results) among aspirin users was significantly shorter, as compared to aspirin nonusers (19.8 ± 7.8 vs. 21.9 ± 7.9 P = 0.045). Among hospitalized COVID-positive patients, a higher proportion of surviving subjects were treated with aspirin (20, 19.05%), as opposed to 1 dead subject (14.29%), although this difference was not significant (P = 0.449). In conclusion, we observed an inverse association between the likelihood of COVID-19 infection, disease duration and mortality, and aspirin use for primary prevention. Acetylsalicylic acid (aspirin) is commonly used for primary and secondary prevention of cardiovascular diseases. Aspirin use is associated with better outcomes among COVID‐19 positive patients. We hypothesized that the aspirin use for primary cardiovascular disease prevention might have a protective effect on COVID‐19 susceptibility and disease duration. We conducted a retrospective population‐based cross‐sectional study, utilizing data from the Leumit Health Services database. The proportion of patients treated with aspirin was significantly lower among the COVID‐19‐positive group, as compared to the COVID‐19‐negative group [73 (11.03%) vs. 1548 (15.77%); P = 0.001]. Aspirin use was associated with lower likelihood of COVID‐19 infection, as compared to nonusers (adjusted OR 0.71 (95% CI, 0.52 to 0.99; P = 0.041). Aspirin users were older (68.06 ± 12.79 vs. 56.63 ± 12.28 years of age; P < 0.001), presented a lower BMI (28.77 ± 5.4 vs. 30.37 ± 4.55; P < 0.0189), and showed higher prevalence of hypertension (56, 76.71%), diabetes (47, 64.38%), and COPD (11, 15.07%) than the aspirin nonusers (151, 25.64%, P < 0.001; 130, 22.07%, P < 0.001; and 43, 7.3%, P = 0.023, respectively). Moreover, COVID‐19 disease duration (considered as the time between the first positive and second negative COVID‐19 RT–PCR test results) among aspirin users was significantly shorter, as compared to aspirin nonusers (19.8 ± 7.8 vs. 21.9 ± 7.9 P = 0.045). Among hospitalized COVID‐positive patients, a higher proportion of surviving subjects were treated with aspirin (20, 19.05%), as opposed to 1 dead subject (14.29%), although this difference was not significant ( P = 0.449). In conclusion, we observed an inverse association between the likelihood of COVID‐19 infection, disease duration and mortality, and aspirin use for primary prevention. Acetylsalicylic acid (aspirin) is used for the prevention of cardiovascular diseases and might be associated with better outcomes among COVID‐19 patients. We hypothesized that aspirin use for primary cardiovascular disease prevention might have effects on COVID‐19 susceptibility. We conducted a retrospective population‐based study, utilizing data from the Leumit Health Services database. We observed an inverse association between the likelihood of COVID‐19 infection, disease duration and mortality, and aspirin use for primary prevention. Acetylsalicylic acid (aspirin) is commonly used for primary and secondary prevention of cardiovascular diseases. Aspirin use is associated with better outcomes among COVID‐19 positive patients. We hypothesized that the aspirin use for primary cardiovascular disease prevention might have a protective effect on COVID‐19 susceptibility and disease duration. We conducted a retrospective population‐based cross‐sectional study, utilizing data from the Leumit Health Services database. The proportion of patients treated with aspirin was significantly lower among the COVID‐19‐positive group, as compared to the COVID‐19‐negative group [73 (11.03%) vs. 1548 (15.77%); P = 0.001]. Aspirin use was associated with lower likelihood of COVID‐19 infection, as compared to nonusers (adjusted OR 0.71 (95% CI, 0.52 to 0.99; P = 0.041). Aspirin users were older (68.06 ± 12.79 vs. 56.63 ± 12.28 years of age; P < 0.001), presented a lower BMI (28.77 ± 5.4 vs. 30.37 ± 4.55; P < 0.0189), and showed higher prevalence of hypertension (56, 76.71%), diabetes (47, 64.38%), and COPD (11, 15.07%) than the aspirin nonusers (151, 25.64%, P < 0.001; 130, 22.07%, P < 0.001; and 43, 7.3%, P = 0.023, respectively). Moreover, COVID‐19 disease duration (considered as the time between the first positive and second negative COVID‐19 RT–PCR test results) among aspirin users was significantly shorter, as compared to aspirin nonusers (19.8 ± 7.8 vs. 21.9 ± 7.9 P = 0.045). Among hospitalized COVID‐positive patients, a higher proportion of surviving subjects were treated with aspirin (20, 19.05%), as opposed to 1 dead subject (14.29%), although this difference was not significant ( P = 0.449). In conclusion, we observed an inverse association between the likelihood of COVID‐19 infection, disease duration and mortality, and aspirin use for primary prevention. Acetylsalicylic acid (aspirin) is commonly used for primary and secondary prevention of cardiovascular diseases. Aspirin use is associated with better outcomes among COVID‐19 positive patients. We hypothesized that the aspirin use for primary cardiovascular disease prevention might have a protective effect on COVID‐19 susceptibility and disease duration. We conducted a retrospective population‐based cross‐sectional study, utilizing data from the Leumit Health Services database. The proportion of patients treated with aspirin was significantly lower among the COVID‐19‐positive group, as compared to the COVID‐19‐negative group [73 (11.03%) vs. 1548 (15.77%); P = 0.001]. Aspirin use was associated with lower likelihood of COVID‐19 infection, as compared to nonusers (adjusted OR 0.71 (95% CI, 0.52 to 0.99; P = 0.041). Aspirin users were older (68.06 ± 12.79 vs. 56.63 ± 12.28 years of age; P < 0.001), presented a lower BMI (28.77 ± 5.4 vs. 30.37 ± 4.55; P < 0.0189), and showed higher prevalence of hypertension (56, 76.71%), diabetes (47, 64.38%), and COPD (11, 15.07%) than the aspirin nonusers (151, 25.64%, P < 0.001; 130, 22.07%, P < 0.001; and 43, 7.3%, P = 0.023, respectively). Moreover, COVID‐19 disease duration (considered as the time between the first positive and second negative COVID‐19 RT–PCR test results) among aspirin users was significantly shorter, as compared to aspirin nonusers (19.8 ± 7.8 vs. 21.9 ± 7.9 P = 0.045). Among hospitalized COVID‐positive patients, a higher proportion of surviving subjects were treated with aspirin (20, 19.05%), as opposed to 1 dead subject (14.29%), although this difference was not significant (P = 0.449). In conclusion, we observed an inverse association between the likelihood of COVID‐19 infection, disease duration and mortality, and aspirin use for primary prevention. Acetylsalicylic acid (aspirin) is commonly used for primary and secondary prevention of cardiovascular diseases. Aspirin use is associated with better outcomes among COVID‐19 positive patients. We hypothesized that the aspirin use for primary cardiovascular disease prevention might have a protective effect on COVID‐19 susceptibility and disease duration. We conducted a retrospective population‐based cross‐sectional study, utilizing data from the Leumit Health Services database. The proportion of patients treated with aspirin was significantly lower among the COVID‐19‐positive group, as compared to the COVID‐19‐negative group [73 (11.03%) vs. 1548 (15.77%); P = 0.001]. Aspirin use was associated with lower likelihood of COVID‐19 infection, as compared to nonusers (adjusted OR 0.71 (95% CI, 0.52 to 0.99; P = 0.041). Aspirin users were older (68.06 ± 12.79 vs. 56.63 ± 12.28 years of age; P < 0.001), presented a lower BMI (28.77 ± 5.4 vs. 30.37 ± 4.55; P < 0.0189), and showed higher prevalence of hypertension (56, 76.71%), diabetes (47, 64.38%), and COPD (11, 15.07%) than the aspirin nonusers (151, 25.64%, P < 0.001; 130, 22.07%, P < 0.001; and 43, 7.3%, P = 0.023, respectively). Moreover, COVID‐19 disease duration (considered as the time between the first positive and second negative COVID‐19 RT–PCR test results) among aspirin users was significantly shorter, as compared to aspirin nonusers (19.8 ± 7.8 vs. 21.9 ± 7.9 P = 0.045). Among hospitalized COVID‐positive patients, a higher proportion of surviving subjects were treated with aspirin (20, 19.05%), as opposed to 1 dead subject (14.29%), although this difference was not significant (P = 0.449). In conclusion, we observed an inverse association between the likelihood of COVID‐19 infection, disease duration and mortality, and aspirin use for primary prevention. Acetylsalicylic acid (aspirin) is used for the prevention of cardiovascular diseases and might be associated with better outcomes among COVID‐19 patients. We hypothesized that aspirin use for primary cardiovascular disease prevention might have effects on COVID‐19 susceptibility. We conducted a retrospective population‐based study, utilizing data from the Leumit Health Services database. We observed an inverse association between the likelihood of COVID‐19 infection, disease duration and mortality, and aspirin use for primary prevention. Acetylsalicylic acid (aspirin) is commonly used for primary and secondary prevention of cardiovascular diseases. Aspirin use is associated with better outcomes among COVID-19 positive patients. We hypothesized that the aspirin use for primary cardiovascular disease prevention might have a protective effect on COVID-19 susceptibility and disease duration. We conducted a retrospective population-based cross-sectional study, utilizing data from the Leumit Health Services database. The proportion of patients treated with aspirin was significantly lower among the COVID-19-positive group, as compared to the COVID-19-negative group [73 (11.03%) vs. 1548 (15.77%); P = 0.001]. Aspirin use was associated with lower likelihood of COVID-19 infection, as compared to nonusers (adjusted OR 0.71 (95% CI, 0.52 to 0.99; P = 0.041). Aspirin users were older (68.06 ± 12.79 vs. 56.63 ± 12.28 years of age; P < 0.001), presented a lower BMI (28.77 ± 5.4 vs. 30.37 ± 4.55; P < 0.0189), and showed higher prevalence of hypertension (56, 76.71%), diabetes (47, 64.38%), and COPD (11, 15.07%) than the aspirin nonusers (151, 25.64%, P < 0.001; 130, 22.07%, P < 0.001; and 43, 7.3%, P = 0.023, respectively). Moreover, COVID-19 disease duration (considered as the time between the first positive and second negative COVID-19 RT-PCR test results) among aspirin users was significantly shorter, as compared to aspirin nonusers (19.8 ± 7.8 vs. 21.9 ± 7.9 P = 0.045). Among hospitalized COVID-positive patients, a higher proportion of surviving subjects were treated with aspirin (20, 19.05%), as opposed to 1 dead subject (14.29%), although this difference was not significant (P = 0.449). In conclusion, we observed an inverse association between the likelihood of COVID-19 infection, disease duration and mortality, and aspirin use for primary prevention. |
| Author | Merzon, Eugene Magen, Eli Green, Ilan Gorohovski, Alessandro Avramovich, Eva Vinker, Shlomo Golan‐Cohen, Avivit Frenkel‐Morgenstern, Milana |
| AuthorAffiliation | 1 Leumit Health Services Tel‐Aviv Israel 3 Department of Management Bar‐Ilan University Safed Israel 5 Medicine C Department Clinical Immunology and Allergy Division Barzilai University Medical Center Ben‐Gurion University of the Negev Ashkelon Israel 2 Department of Family Medicine Sackler Faculty of Medicine Tel‐Aviv University Israel 4 Azrieli Faculty of Medicine Bar‐Ilan University Safed Israel |
| AuthorAffiliation_xml | – name: 4 Azrieli Faculty of Medicine Bar‐Ilan University Safed Israel – name: 2 Department of Family Medicine Sackler Faculty of Medicine Tel‐Aviv University Israel – name: 5 Medicine C Department Clinical Immunology and Allergy Division Barzilai University Medical Center Ben‐Gurion University of the Negev Ashkelon Israel – name: 3 Department of Management Bar‐Ilan University Safed Israel – name: 1 Leumit Health Services Tel‐Aviv Israel |
| Author_xml | – sequence: 1 givenname: Eugene surname: Merzon fullname: Merzon, Eugene organization: Tel‐Aviv University – sequence: 2 givenname: Ilan surname: Green fullname: Green, Ilan organization: Tel‐Aviv University – sequence: 3 givenname: Shlomo surname: Vinker fullname: Vinker, Shlomo organization: Tel‐Aviv University – sequence: 4 givenname: Avivit surname: Golan‐Cohen fullname: Golan‐Cohen, Avivit organization: Tel‐Aviv University – sequence: 5 givenname: Alessandro surname: Gorohovski fullname: Gorohovski, Alessandro organization: Bar‐Ilan University – sequence: 6 givenname: Eva surname: Avramovich fullname: Avramovich, Eva organization: Bar‐Ilan University – sequence: 7 givenname: Milana orcidid: 0000-0002-0329-4599 surname: Frenkel‐Morgenstern fullname: Frenkel‐Morgenstern, Milana email: milana.morgenstern@biu.ac.il organization: Bar‐Ilan University – sequence: 8 givenname: Eli surname: Magen fullname: Magen, Eli organization: Ben‐Gurion University of the Negev |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33621437$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkstuEzEUhi3Uil5gwwMgS2wQUoo9vsx4gwShpZUqdUFB7CyPfYa4OONgZxJ1B2_AM_IkeEiIoELgzbF0vv_XuR2hvT72gNAjSk5oec87aPMJFXXD76FDWvNqwqVo9nZ__uEAHeV8QwgTXKn76IAxWVHO6kP09XoGeMiAY4dNXvjke9zFhBfJz026LRFW0C997EfCmuR8XJlsh2ASdj6DKVqfizZH680SHF775QwbHOIaEg7-EwQ_i9GN-unV-4vX3798owr7vgM7-j5A-50JGR5u4zF6d3Z6PT2fXF69uZi-vJxYQRSfmAqcAwWEcQmCiNpZ65QkHQHZck7rtm2bkuDKkUa2dVOVIZim5awzbVULdoxebHwXQzsHZ0tXyQS9bVRH4_Wfmd7P9Me40g2hrBajwdOtQYqfB8hLPffZQgimhzhkXUkmZa1IGfN_Ua5YwRraFPTJHfQmDqkvk9CVkIorQRUt1OPfi99V_WuRBXi2AWyKOSfodgglerwSPV6J_nklBSZ3YOuXZlxGadyHv0voRrL2AW7_Ya7PTl-93Wh-AFFL0Vs |
| CitedBy_id | crossref_primary_10_1016_j_jbior_2021_100819 crossref_primary_10_1038_s41598_022_16396_9 crossref_primary_10_1038_s41598_024_82225_w crossref_primary_10_1002_rth2_12743 crossref_primary_10_3390_vaccines10010074 crossref_primary_10_1055_s_0042_1744281 crossref_primary_10_1007_s11239_024_03028_4 crossref_primary_10_2174_1381612829666221107123841 crossref_primary_10_3390_jcm11185454 crossref_primary_10_1016_j_eclinm_2022_101373 crossref_primary_10_2174_1871525720666220401102728 crossref_primary_10_1016_j_tru_2021_100065 crossref_primary_10_1007_s12519_024_00798_y crossref_primary_10_1055_a_1965_1598 crossref_primary_10_1016_j_ijid_2021_05_016 crossref_primary_10_1016_S1473_3099_22_00433_9 crossref_primary_10_1080_13543784_2021_1950687 crossref_primary_10_2147_PPA_S437822 crossref_primary_10_1016_j_rec_2023_12_004 crossref_primary_10_3389_fendo_2021_772865 crossref_primary_10_1002_hsr2_699 crossref_primary_10_1016_j_recesp_2023_12_012 crossref_primary_10_5501_wjv_v13_i2_92521 crossref_primary_10_12677_acm_2024_1472094 crossref_primary_10_1007_s12519_021_00499_w crossref_primary_10_1055_a_1380_2016 crossref_primary_10_3389_fmed_2022_965790 crossref_primary_10_3389_fphar_2022_989903 crossref_primary_10_1096_fj_202100540R crossref_primary_10_1111_ijcp_14515 crossref_primary_10_1002_cmdc_202200157 crossref_primary_10_1080_13814788_2022_2138855 crossref_primary_10_1515_revneuro_2021_0047 crossref_primary_10_1111_febs_16167 crossref_primary_10_1016_j_jns_2021_117463 crossref_primary_10_2147_JEP_S330776 |
| Cites_doi | 10.1080/22221751.2020.1739565 10.1016/j.jacc.2019.03.010 10.1023/B:EJEP.0000006635.36802.c8 10.1016/S0140-6736(20)30183-5 10.1016/S0140-6736(18)31924-X 10.1111/bjh.14520 10.1161/CIRCRESAHA.120.317703 10.1016/j.immuni.2014.02.013 10.1038/nrmicro.2016.81 10.1186/s13045-020-00954-7 10.1038/s41586-020-2008-3 10.1111/bph.15082 10.1093/jmcb/mjp048 10.1016/j.cell.2020.05.032 10.1002/jcp.30032 10.1016/j.intimp.2011.11.021 10.1001/jama.2020.5394 10.1016/j.dsx.2020.07.011 10.4097/kja.19087 10.1055/s-0040-1710317 10.1016/j.immuni.2019.03.025 10.1182/blood.2020007214 10.1080/22221751.2020.1785336 10.1213/ANE.0000000000005292 10.1158/1940-6207.CAPR-16-0094 10.1164/rccm.202003-0524LE 10.1111/irv.12421 10.1056/NEJMoa1803955 10.1038/s41569-019-0225-y 10.1016/j.ebiom.2020.102801 |
| ContentType | Journal Article |
| Copyright | 2021 Federation of European Biochemical Societies 2021 Federation of European Biochemical Societies. Copyright © 2021 Federation of European Biochemical Societies |
| Copyright_xml | – notice: 2021 Federation of European Biochemical Societies – notice: 2021 Federation of European Biochemical Societies. – notice: Copyright © 2021 Federation of European Biochemical Societies |
| DBID | AAYXX CITATION NPM 7QL 7QP 7QR 7TK 7TM 7U9 8FD C1K FR3 H94 M7N P64 RC3 7X8 7S9 L.6 5PM |
| DOI | 10.1111/febs.15784 |
| DatabaseName | CrossRef PubMed Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Neurosciences Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed Virology and AIDS Abstracts Technology Research Database Nucleic Acids Abstracts Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management Genetics Abstracts Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts Chemoreception Abstracts Engineering Research Database Calcium & Calcified Tissue Abstracts MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | MEDLINE - Academic CrossRef Virology and AIDS Abstracts PubMed AGRICOLA |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology Chemistry |
| DocumentTitleAlternate | The use of aspirin lowers COVID‐19 susceptibility |
| EISSN | 1742-4658 |
| EndPage | 5189 |
| ExternalDocumentID | PMC8013755 33621437 10_1111_febs_15784 FEBS15784 |
| Genre | article Journal Article |
| GrantInformation_xml | – fundername: Israel Innovation Authority, Kamin grant funderid: 66824 – fundername: COVID‐19 Data Science Institute (DSI) Grant, Bar‐Ilan University funderid: 247017 – fundername: COVID-19 Data Science Institute (DSI) Grant, Bar-Ilan University grantid: 247017 – fundername: Israel Innovation Authority, Kamin grant grantid: 66824 – fundername: COVID‐19 Data Science Institute (DSI) Grant, Bar‐Ilan University grantid: 247017 |
| GroupedDBID | --- -DZ -~X .3N .55 .GA .Y3 05W 0R~ 10A 1OC 24P 29H 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 A8Z AAESR AAEVG AAHBH AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEFU ABEML ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFS ACGOF ACIWK ACMXC ACNCT ACPOU ACPRK ACSCC ACUHS ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C1A C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM E3Z EAD EAP EAS EAU EBB EBC EBD EBS EBX EJD EMB EMK EMOBN EST ESX EX3 F00 F01 F04 F5P FIJ FUBAC G-S G.N GODZA GX1 H.X HF~ HGLYW HH5 HZI HZ~ IHE IX1 J0M KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MVM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OBS OIG OK1 OVD P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 R.K RNS ROL RX1 SUPJJ SV3 TEORI TR2 TUS UB1 V8K W8V W99 WBFHL WBKPD WIH WIJ WIK WIN WOHZO WOQ WOW WQJ WRC WXI WXSBR WYISQ X7M XG1 Y6R ~IA ~KM ~WT AAYXX AEYWJ AGHNM AGYGG CITATION NPM 7QL 7QP 7QR 7TK 7TM 7U9 8FD AAMMB AEFGJ AGXDD AIDQK AIDYY C1K FR3 H94 M7N P64 RC3 7X8 7S9 L.6 5PM |
| ID | FETCH-LOGICAL-c5094-a2edde9e0346e5057dccd960f0e6b4417bbb8e5049d086b782465a8b43fab2753 |
| IEDL.DBID | DR2 |
| ISSN | 1742-464X 1742-4658 |
| IngestDate | Thu Aug 21 18:28:37 EDT 2025 Fri Jul 11 18:34:06 EDT 2025 Thu Jul 10 18:27:57 EDT 2025 Fri Jul 25 09:21:09 EDT 2025 Wed Feb 19 02:28:55 EST 2025 Tue Jul 01 03:06:53 EDT 2025 Thu Apr 24 23:01:25 EDT 2025 Wed Jan 22 16:29:08 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 17 |
| Keywords | COVID-19 Israeli cohort aspirin disease likelihood |
| Language | English |
| License | 2021 Federation of European Biochemical Societies. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5094-a2edde9e0346e5057dccd960f0e6b4417bbb8e5049d086b782465a8b43fab2753 |
| Notes | Eugene Merzon and Ilan Green contributed equally to this article ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-0329-4599 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8013755 |
| PMID | 33621437 |
| PQID | 2569495191 |
| PQPubID | 28478 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8013755 proquest_miscellaneous_2636679000 proquest_miscellaneous_2493003818 proquest_journals_2569495191 pubmed_primary_33621437 crossref_primary_10_1111_febs_15784 crossref_citationtrail_10_1111_febs_15784 wiley_primary_10_1111_febs_15784_FEBS15784 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | September 2021 |
| PublicationDateYYYYMMDD | 2021-09-01 |
| PublicationDate_xml | – month: 09 year: 2021 text: September 2021 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Oxford – name: Hoboken |
| PublicationTitle | The FEBS journal |
| PublicationTitleAlternate | FEBS J |
| PublicationYear | 2021 |
| Publisher | Blackwell Publishing Ltd John Wiley and Sons Inc |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: John Wiley and Sons Inc |
| References | 2019; 50 2019; 72 2019; 74 2020; 120 2020; 182 2019; 16 2020; 127 2020; 14 2020; 13 2003; 18 2020; 56 2020; 323 2020; 201 2017; 177 2014; 40 2012; 12 2016; 14 2018; 392 2021; 236 2020; 395 2020 2017; 11 1995; 45 2018; 379 2020; 9 2020; 579 2001; 3 2020; 177 2016 2020; 136 2010; 2 2016; 9 e_1_2_10_23_1 e_1_2_10_24_1 e_1_2_10_21_1 e_1_2_10_22_1 e_1_2_10_20_1 e_1_2_10_41_1 e_1_2_10_40_1 Pringle M (e_1_2_10_10_1) 1995; 45 e_1_2_10_2_1 e_1_2_10_4_1 e_1_2_10_18_1 e_1_2_10_3_1 e_1_2_10_19_1 e_1_2_10_6_1 e_1_2_10_16_1 e_1_2_10_39_1 e_1_2_10_5_1 e_1_2_10_17_1 e_1_2_10_38_1 e_1_2_10_8_1 e_1_2_10_14_1 e_1_2_10_37_1 e_1_2_10_7_1 e_1_2_10_15_1 e_1_2_10_36_1 e_1_2_10_35_1 e_1_2_10_9_1 Rennert G (e_1_2_10_12_1) 2001; 3 e_1_2_10_13_1 e_1_2_10_34_1 e_1_2_10_33_1 e_1_2_10_32_1 e_1_2_10_31_1 e_1_2_10_30_1 Rennert G (e_1_2_10_11_1) 2001; 3 e_1_2_10_29_1 e_1_2_10_27_1 e_1_2_10_28_1 e_1_2_10_25_1 e_1_2_10_26_1 |
| References_xml | – volume: 379 start-page: 1519 year: 2018 end-page: 1528 article-title: Effect of aspirin on all‐cause mortality in the healthy elderly publication-title: N Engl J Med – volume: 13 start-page: 120 year: 2020 article-title: SARS‐CoV‐2 binds platelet ACE2 to enhance thrombosis in COVID‐19 publication-title: J Hematol Oncol – volume: 9 start-page: 855 year: 2016 end-page: 865 article-title: Inhibition of the biosynthesis of prostaglandin E2 by low‐dose aspirin: implications for adenocarcinoma metastasis publication-title: Cancer Prev Res (Phila) – volume: 72 start-page: 558 year: 2019 end-page: 569 article-title: Multicollinearity and misleading statistical results publication-title: Korean J Anesthesiol – volume: 236 start-page: 2364 year: 2021 end-page: 2392 article-title: Targeted therapy strategies against SARS‐CoV‐2 cell entry mechanisms: a systematic review of in vitro and in vivo studies publication-title: J Cell Physiol – volume: 201 start-page: 1150 year: 2020 end-page: 1152 article-title: Time kinetics of viral clearance and resolution of symptoms in novel coronavirus infection publication-title: Am J Respir Crit Care Med – year: 2020 article-title: Aspirin use is associated with decreased mechanical ventilation, ICU admission, and in‐hospital mortality in hospitalized patients with COVID‐19 publication-title: Anesth Analg – volume: 177 start-page: 4825 year: 2020 end-page: 4844 article-title: A hypothesis for pathobiology and treatment of COVID‐19: the centrality of ACE1/ACE2 imbalance publication-title: Br J Pharmacol – volume: 18 start-page: 1143 year: 2003 end-page: 1146 article-title: The epidemiology of diabetes in a large Israeli HMO publication-title: Eur J Epidemiol – volume: 3 start-page: 404 year: 2001 end-page: 408 article-title: Prevalence of selected chronic diseases in Israel publication-title: Isr Med Assoc J – volume: 136 start-page: 1317 year: 2020 end-page: 1329 article-title: Platelet gene expression and function in patients with COVID‐19 publication-title: Blood – volume: 45 start-page: 537 year: 1995 end-page: 541 article-title: Assessment of the completeness and accuracy of computer medical records in four practices committed to recording data on computer publication-title: Br J Gen Pract – volume: 2 start-page: 110 year: 2010 end-page: 112 article-title: STING‐ing the antiviral pathway publication-title: J Mol Cell Biol – volume: 11 start-page: 85 year: 2017 end-page: 92 article-title: Antiviral activity of aspirin against RNA viruses of the respiratory tract‐an in vitro study publication-title: Influenza Other Respir Viruses – volume: 9 start-page: 1514 year: 2020 end-page: 1522 article-title: Kawasaki‐like diseases and thrombotic coagulopathy in COVID‐19: delayed over‐activation of the STING pathway? publication-title: Emerg Microbes Infect – year: 2016 – volume: 177 start-page: 674 year: 2017 end-page: 683 article-title: The aspirin story – from willow to wonder drug publication-title: Br J Haematol – volume: 74 start-page: e177 year: 2019 end-page: e232 article-title: 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines publication-title: J Am Coll Cardiol – volume: 120 start-page: 949 year: 2020 end-page: 956 article-title: Hypercoagulation and antithrombotic treatment in coronavirus 2019: a new challenge publication-title: Thromb Haemost – volume: 395 start-page: 497 year: 2020 end-page: 506 article-title: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China publication-title: Lancet – volume: 9 start-page: 601 year: 2020 end-page: 604 article-title: Emerging WuHan (COVID‐19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26 publication-title: Emerg Microbes Infect – volume: 40 start-page: 554 year: 2014 end-page: 568 article-title: Targeted prostaglandin E2 inhibition enhances antiviral immunity through induction of type I interferon and apoptosis in macrophages publication-title: Immunity – volume: 16 start-page: 675 year: 2019 end-page: 686 article-title: Role of aspirin in primary prevention of cardiovascular disease publication-title: Nat Rev Cardiol – volume: 182 start-page: 59 year: 2020 end-page: 72 article-title: Proteomic and metabolomic characterization of COVID‐19 patient sera publication-title: Cell – year: 2020 – volume: 12 start-page: 10 year: 2012 end-page: 20 article-title: Aspirin and immune system publication-title: Int Immunopharmacol – volume: 14 start-page: 523 year: 2016 end-page: 534 article-title: SARS and MERS: recent insights into emerging coronaviruses publication-title: Nat Rev Microbiol – volume: 50 start-page: 907 year: 2019 end-page: 923 article-title: Shared and distinct functions of type I and type III interferons publication-title: Immunity – volume: 392 start-page: 1036 year: 2018 end-page: 1046 article-title: Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double‐blind, placebo‐controlled trial publication-title: Lancet – volume: 579 start-page: 265 year: 2020 end-page: 269 article-title: A new coronavirus associated with human respiratory disease in China publication-title: Nature – volume: 323 start-page: 1574 year: 2020 end-page: 1581 article-title: Baseline characteristics and outcomes of 1591 patients infected with SARS‐CoV‐2 admitted to ICUs of the Lombardy Region, Italy publication-title: JAMA – volume: 56 year: 2020 article-title: COVID‐19 as a STING disorder with delayed over‐secretion of interferon‐beta publication-title: EBioMedicine – volume: 14 start-page: 1225 year: 2020 end-page: 1229 article-title: Pros and cons for use of statins in people with coronavirus disease‐19 (COVID‐19) publication-title: Diabetes Metab Syndr – volume: 127 start-page: 1404 year: 2020 end-page: 1418 article-title: Platelets can associate with SARS‐Cov‐2 RNA and are hyperactivated in COVID‐19 publication-title: Circ Res – ident: e_1_2_10_34_1 doi: 10.1080/22221751.2020.1739565 – ident: e_1_2_10_7_1 doi: 10.1016/j.jacc.2019.03.010 – ident: e_1_2_10_41_1 – ident: e_1_2_10_13_1 doi: 10.1023/B:EJEP.0000006635.36802.c8 – ident: e_1_2_10_3_1 doi: 10.1016/S0140-6736(20)30183-5 – ident: e_1_2_10_39_1 – ident: e_1_2_10_5_1 doi: 10.1016/S0140-6736(18)31924-X – ident: e_1_2_10_36_1 – ident: e_1_2_10_4_1 doi: 10.1111/bjh.14520 – ident: e_1_2_10_30_1 doi: 10.1161/CIRCRESAHA.120.317703 – ident: e_1_2_10_21_1 doi: 10.1016/j.immuni.2014.02.013 – ident: e_1_2_10_18_1 doi: 10.1038/nrmicro.2016.81 – ident: e_1_2_10_32_1 doi: 10.1186/s13045-020-00954-7 – ident: e_1_2_10_40_1 – ident: e_1_2_10_22_1 doi: 10.1038/s41586-020-2008-3 – ident: e_1_2_10_27_1 doi: 10.1111/bph.15082 – ident: e_1_2_10_24_1 doi: 10.1093/jmcb/mjp048 – ident: e_1_2_10_31_1 doi: 10.1016/j.cell.2020.05.032 – volume: 45 start-page: 537 year: 1995 ident: e_1_2_10_10_1 article-title: Assessment of the completeness and accuracy of computer medical records in four practices committed to recording data on computer publication-title: Br J Gen Pract – ident: e_1_2_10_33_1 doi: 10.1002/jcp.30032 – ident: e_1_2_10_9_1 doi: 10.1016/j.intimp.2011.11.021 – ident: e_1_2_10_2_1 doi: 10.1001/jama.2020.5394 – ident: e_1_2_10_23_1 doi: 10.1016/j.dsx.2020.07.011 – ident: e_1_2_10_35_1 doi: 10.4097/kja.19087 – ident: e_1_2_10_19_1 doi: 10.1016/j.immuni.2014.02.013 – ident: e_1_2_10_38_1 doi: 10.1055/s-0040-1710317 – ident: e_1_2_10_17_1 doi: 10.1016/j.immuni.2019.03.025 – ident: e_1_2_10_15_1 – ident: e_1_2_10_29_1 doi: 10.1182/blood.2020007214 – ident: e_1_2_10_14_1 – ident: e_1_2_10_26_1 doi: 10.1080/22221751.2020.1785336 – volume: 3 start-page: 404 year: 2001 ident: e_1_2_10_11_1 article-title: Prevalence of selected chronic diseases in Israel publication-title: Isr Med Assoc J – ident: e_1_2_10_28_1 doi: 10.1213/ANE.0000000000005292 – ident: e_1_2_10_20_1 doi: 10.1158/1940-6207.CAPR-16-0094 – ident: e_1_2_10_37_1 doi: 10.1164/rccm.202003-0524LE – volume: 3 start-page: 404 year: 2001 ident: e_1_2_10_12_1 article-title: Prevalence of selected chronic diseases in Israel publication-title: Isr Med Assoc J – ident: e_1_2_10_16_1 doi: 10.1111/irv.12421 – ident: e_1_2_10_6_1 doi: 10.1056/NEJMoa1803955 – ident: e_1_2_10_8_1 doi: 10.1038/s41569-019-0225-y – ident: e_1_2_10_25_1 doi: 10.1016/j.ebiom.2020.102801 |
| SSID | ssj0035499 |
| Score | 2.5360832 |
| Snippet | Acetylsalicylic acid (aspirin) is commonly used for primary and secondary prevention of cardiovascular diseases. Aspirin use is associated with better outcomes... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 5179 |
| SubjectTerms | Acetylsalicylic acid Aspirin Cardiovascular disease Cardiovascular diseases Chronic obstructive pulmonary disease COVID-19 COVID-19 infection cross-sectional studies diabetes Diabetes mellitus Disease control disease likelihood Disease prevention Hypertension Infections Israeli cohort mortality Original Population studies protective effect Viral diseases |
| Title | The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID‐19 infection |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Ffebs.15784 https://www.ncbi.nlm.nih.gov/pubmed/33621437 https://www.proquest.com/docview/2569495191 https://www.proquest.com/docview/2493003818 https://www.proquest.com/docview/2636679000 https://pubmed.ncbi.nlm.nih.gov/PMC8013755 |
| Volume | 288 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwEB1VvZRLgZZCaLsyAiG1UlabtfMlcVmWrkqlgkRbtBcU2Y4tVl2yFdk9lBP8g_7G_pLOOB90KaoEp0TyOIqdcfzGfn4D8MpoyXkshJ_2RO4LjRhOBjH3Y8Ot5TYRSUiHk48_RIdn4mgcjlfgTXMWptKHaBfcaGS4_zUNcKnKW4PcGlV2A3Q4EgMlshYhok-tdhSnwKc6Ddn3RSTGtTYp0Xh-V12eje5AzLtMydsI1k1Bo4fwpXn5inly3l3MVVf_-EPX8X9b9wjWa2zKBpUzPYYVU2zA5qDAuPzbJXvNHFvULcNvwNqwyRS3Cb_Q19iiNGxmmaSd-0nBEAuzi0rJAq-mZlWShV5iwLJ6h4hNSqxbuYrJGS0PM8mmlMONTSfn2BrSX6b6w4-f37-7_nkVpKxhkhVP4Gx0cDo89OvUDr4mxT5f9g3-V1PT4yIyFCPlWucYTNmeiRRlRVNKJVgg0hxjLoUwRkShTJTgVqo-hlhbsFrMCvMMmMZahqsgyFMtdKoR8OJzY5nkJrS2F3iw13ziTNe655R-Y5o18Q_1deb62oOXrW3dR3-12mk8JatHfJkhdEwx2MTw14MXbTF-CNqAkYWZLdBGpLzamr3HJuJRFFMqVw-eVs7XvgpHtIH4NvYgXnLL1oC0wpdLislXpxmekLRkGHqw77zuntZlo4O3J-7u-b8Yb8ODPtF9HP1uB1bn3xdmF_HaXHXcuOzQnBneANbNQMY |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LbxMxEB5BOZQLj5bHQgEjEBJIG2Vj7-tY0kYptEWCFuW2sr22iJpuKjY5wAn-Ab-RX8KM17s0FFWCUyJ5HMX2zO439udvAJ4bLTlPhQjzvihDoRHDySjlYWq4tdxmIovpcvLBYTI-Fm8m8cRzc-guTKMP0W24UWS45zUFOG1In4tya1Tdi9DjxFW4RiW9STp_532nHsUp9WnuQw5CkYiJVyclIs_vvqvvowsg8yJX8jyGdS-h0c2m0mrttAuJe3LSWy5UT3_9Q9nxv8d3C254eMq2G3-6DVdMtQGb2xWm5qdf2AvmCKNuJ34D1odtsbhN-I7uxpa1YXPLJB3eTyuGcJidNWIW-Gk8sZIs9AoJlvlDIjatsW_jLaZktEPMJJtRGTc2m57gcEiCmfoP333c2_n57UeUs5ZMVt2B49Hu0XAc-uoOoSbRvlAODD5ac9PnIjGUJpVal5hP2b5JFBVGU0pl2CDyEtMuhUgG11hmSnAr1QCzrLuwVs0rcx-Yxl6Gqygqcy10rhHz4u-mMitNbG0_CuBlu8aF9tLnVIFjVrQpEM114eY6gGedrZ-jv1ptta5S-KCvC0SPOeabmAEH8LRrxoWgMxhZmfkSbUTOm9PZS2wSniQpVXMN4F7jfd1f4Qg4EOKmAaQrftkZkFz4aks1_eRkwzNSl4zjAF45t7tkdMVo9_UH9-3Bvxg_gfXx0cF-sb93-PYhXB8Q-8ex8bZgbfF5aR4hfFuoxy5IfwEeP0P8 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFD4aQwJeuGxcAgOMQEggpUpqx0kkXka7auMyEDDUFxTZji2qlXSi7QM8wT_gN_JLOMe5sDI0CZ4aycdV7JyTfJ99_B2AB9YozlMhwjwSZSgMYjgVpzxMLXeOu0xkCR1Ofrkvdw_Es3EyXoMn7VmYWh-iW3CjyPDvawrwo9IdC3Jn9bwXo8OJM3BWyCinwg3DN514FCfmUx-H7IdCinEjTkp5PL_7rn6OTmDMk6mSxyGs_waNLsGH9u7r1JPD3nKhe-brH8KO_zu8y3CxAadsu_amK7Bmqw3Y3K6QmH_6wh4yny7q1-E34PygLRW3Cd_R2dhybtnMMUVb95OKIRhmR7WUBf7aJq2SLMxKCixrtojYZI59a1-xJaP1YabYlIq4senkEEdDAszUf_Dq_d7w57cfcc7aVLLqKhyMdt4NdsOmtkNoSLIvVH2LL9bcRlxISySpNKZENuUiKzWVRdNaZ9gg8hJJl0YcI2SiMi24U7qPHOsarFezyt4AZrCX5TqOy9wIkxtEvPi_qcpKmzgXxQE8ah9xYRrhc6q_MS1aAkRzXfi5DuB-Z9vM0V-ttlpPKZqQnxeIHXNkm8h_A7jXNeODoB0YVdnZEm1Ezuu92VNsJJcypVquAVyvna-7FY5wAwFuGkC64padAYmFr7ZUk49eNDwjbckkCeCx97pTRleMdp6-9Vc3_8X4Lpx7PRwVL_b2n9-CC31K_fGpeFuwvvi8tLcRuy30HR-ivwArxkKr |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+use+of+aspirin+for+primary+prevention+of+cardiovascular+disease+is+associated+with+a+lower+likelihood+of+COVID%E2%80%9019+infection&rft.jtitle=The+FEBS+journal&rft.au=Merzon%2C+Eugene&rft.au=Green%2C+Ilan&rft.au=Vinker%2C+Shlomo&rft.au=Golan%E2%80%90Cohen%2C+Avivit&rft.date=2021-09-01&rft.issn=1742-464X&rft.eissn=1742-4658&rft.volume=288&rft.issue=17&rft.spage=5179&rft.epage=5189&rft_id=info:doi/10.1111%2Ffebs.15784&rft.externalDBID=10.1111%252Ffebs.15784&rft.externalDocID=FEBS15784 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1742-464X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1742-464X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1742-464X&client=summon |